Fusion proteins for delivery of gdnf to the cns
AssigneeArmaGen Technologies, Inc.
InventorsWilliam M. Pardridge, Ruben J. Boado
Life of this patent
Estimating the term…
Abstract
The invention provides compositions, methods, and kits for increasing transport of GDNF across the blood brain barrier while allowing its activity to remain substantially intact. The GDNF is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems.
Claims28
A composition comprising a neurotherapeutic peptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of mature human GDNF (SEQ ID NO:52) covalently linked to a structure that is capable of crossing the blood brain barrier (BBB).
A composition for treating a neurological disorder comprising a neurotherapeutic peptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of mature human GDNF (SEQ ID NO:52) covalently linked to an immunoglobulin that is capable of crossing the blood brain barrier, wherein the composition is capable of crossing the BBB in an amount that is effective in treating the neurological disorder.
A method for treating a CNS disorder in an individual comprising peripherally administering to the individual an effective amount of a composition comprising a neurotherapeutic peptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of mature human GDNF (SEQ ID NO:52) covalently attached to a structure capable of crossing the BBB.
A method for treating substance abuse in an individual, comprising administering to the individual an effective amount of a composition comprising a neurotherapeutic peptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of mature human GDNF (SEQ ID NO:52) covalently attached to a structure capable of crossing the BBB.
Dependencies are inferred from the claim text.